Resistance to immune checkpoint blockade (ICB) is a challenge in hepatocellular carcinoma therapy. Here, the authors show that targeting PRMT3 markedly improves the anticancer efficacy of ICB via interrupting HSP60 methylation and oligomerization, damaging mitochondrial integrity, and thereby activating cGAS/STING-mediated anti-tumor immunity.
- Yunxing Shi
- Zongfeng Wu
- Binkui Li
